KeyBanc analyst Paul Knight raised the firm’s price target on Danaher (DHR) to $310 from $290 and keeps an Overweight rating on the shares. The firm notes Danaher reported an earnings beat, but the share price was slightly weaker after the earnings call. The company cited that China was still weak and China stimulus was not a significant positive. KeyBanc thinks the Danaher’s comments reflect the sobering reality of China and industry CapEx headwinds persisting. However, with a world-leading position in bioprocessing and biotechnology research, the firm sees visibility to mid to high single digit growth in FY25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $277 from $278 at Baird
- Danaher price target lowered to $275 from $285 at Barclays
- Danaher price target raised to $255 from $250 at Goldman Sachs
- Morning Movers: 3M gains and GE Aerospace falls following third quarter results
- Danaher backs FY24 revenue view down low-single digits